

Protalix BioTherapeutics, Inc.
Form 3
October 20, 2015

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â Camber Capital Management LLC			(Month/Day/Year)	Protalix BioTherapeutics, Inc. [PLX]	
(Last)	(First)	(Middle)		4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
101 HUNTINGTON AVENUE,Â SUITE 2550				(Check all applicable)	
(Street)				____ Director	__X__ 10% Owner
				____ Officer	____ Other
				(give title below)	(specify below)
BOSTON,Â MAÂ 02199				6. Individual or Joint/Group Filing(Check Applicable Line)	
(City)	(State)	(Zip)		__X__ Form filed by One Reporting Person	
				____ Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	9,274,577	I	See Footnotes <u>(1)</u> <u>(2)</u>
Convertible Note Contracts	1,562,933	I	See Footnotes <u>(1)</u> <u>(3)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security	4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	--	---------------------------	----------------------	--

Edgar Filing: Protalix BioTherapeutics, Inc. - Form 3

Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I)

(Instr. 4)

(Instr. 5)

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Camber Capital Management LLC
101 HUNTINGTON AVENUE
SUITE 2550
BOSTON, MA 02199

^ ^ X ^ ^

Signatures

Stephen DuBois 10/20/2015

Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Securities reported herein for Camber Capital Management LLC (the "LLC") represent Common Stock and Convertible Note Contracts (on an as-covered basis) beneficially owned and held of record by Camber Capital Master Fund, L.P. (the "Fund"), another private investment fund (the "Fund") and one managed account (the "Managed Account") for which the LLC serves as the investment manager.

- (1) Stephen DuBois is the managing member of the LLC and managing member of the general partner for the Fund and the Master Fund. The LLC, the Master Fund, the Fund, the Managed Account, general partner and Mr. DuBois (the "Reporting Persons") are each beneficial owners and have an address of 101 Huntington Avenue, Floor 25, Boston, MA 02199. The Reporting Persons disclaim beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares in which the Reporting Persons have no actual pecuniary interest therein.

- (2) Of the securities reported herein, 8,953,095 shares of Common Stock are held for the account of the Master Fund, 63,057 shares of Common Stock are held for the account of the Fund, and 258,425 shares of Common Stock are held for the account of the Managed Account.

- (3) Of the securities reported herein, 8,541 Convertible Note Contracts (equivalent to 1,483,224 shares of Common Stock on an as-covered basis) are held for the account of the Master Fund, 68 Convertible Note Contracts (equivalent to 11,878 shares of Common Stock on an as-covered basis) are held for the account of the Fund, and 391 Convertible Note Contracts (equivalent to 67,831 shares of Common Stock on an as-covered basis) are held for the account of the Managed Account.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.